Cancer Cachexia - Pipeline Review, H1 2015

Description: Cancer Cachexia - Pipeline Review, H1 2015

Summary

This, 'Cancer Cachexia - Pipeline Review, H1 2015', provides an overview of the Cancer Cachexia's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Cancer Cachexia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cancer Cachexia and special features on late-stage and discontinued projects.

This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Cancer Cachexia
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Cancer Cachexia and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Cancer Cachexia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Cancer Cachexia pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Cancer Cachexia
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Cancer Cachexia pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Contents:
List of Tables
List of Figures
Introduction
REPORT COVERAGE
Cancer Cachexia Overview
Therapeutics Development
Pipeline Products for Cancer Cachexia - Overview
Pipeline Products for Cancer Cachexia - Comparative Analysis
Cancer Cachexia - Therapeutics under Development by Companies
Cancer Cachexia - Therapeutics under Investigation by Universities/Institutes
Cancer Cachexia - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Cancer Cachexia - Products under Development by Companies
Cancer Cachexia - Products under Investigation by Universities/Institutes
Cancer Cachexia - Companies Involved in Therapeutics Development
Acacia Pharma Ltd.
Aeterna Zentaris Inc.
Amgen Inc.
Aphios Corporation
Atara Biotherapeutics, Inc.
Eli Lilly and Company
GTx, Inc.
Helsinn Healthcare S.A.
Incyte Corporation
Novartis AG
Ohr Pharmaceutical Inc.
PsiOxus Therapeutics, Ltd.
Radius Health, Inc.
RaQualia Pharma Inc.
Vicus Therapeutics, LLC
Cancer Cachexia - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
(etodolac + propranolol hydrochloride) - Drug Profile
Product Description
Mechanism of Action
R&D Progress
(formoterol fumarate + megestrol acetate) - Drug Profile
Product Description
Mechanism of Action
R&D Progress
anamorelin hydrochloride - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Antibody to Inhibit Parathyroid Hormone Related Protein for Cancer Cachexia - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Aptamer to Activate Calcineurin A for Genetic Disorders and Musculoskeletal Disorders - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ATA-842 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
bimagrumab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
DCB-CA2 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
dronabinol - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Drug to Antagonize ActRIIB for Cancer Cachexia - Drug Profile
Product Description
Mechanism of Action
R&D Progress
enobosarm - Drug Profile
Product Description
Mechanism of Action
R&D Progress
espindolol - Drug Profile
Product Description
Mechanism of Action
R&D Progress
EXT-400 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
LY-2495655 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
macimorelin acetate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
NBD Peptide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
OHR/AVR-118 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
RAD-140 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
RQ-00432933 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ruxolitinib phosphate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecule to Agonize Ghrelin Receptor for Cancer Cachexia and Anorexia - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecule to Inhibit ATGL for Cancer Cachexia and Type 2 Diabetes - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Synthetic Peptide to Inhibit Melanocortin Receptor for Cancer Cachexia - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Synthetic Peptides for Cancer Cachexia - Drug Profile
Product Description
Mechanism of Action
R&D Progress
VK-5211 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Cancer Cachexia - Recent Pipeline Updates
Cancer Cachexia - Dormant Projects
Cancer Cachexia - Discontinued Products
Cancer Cachexia - Product Development Milestones
Featured News & Press Releases
Oct 30, 2014: New Data on Fatigue from ROMANA 1, a Pivotal Phase III Study of Anamorelin in Advanced NSCLC Patients with Cachexia Presented at 2014 Chicago Multidisciplinary Symposium in Thoracic Oncology
Dec 11, 2013: Phase II Data on OHR/AVR118 in Advanced Cancer Patients With Cachexia Presented at International Cachexia Conference in Kobe, Japan
Oct 24, 2013: GTx Presents Results from Enobosarm POWER Trials for the Prevention and Treatment of Muscle Wasting in Patients with Non-Small Cell Lung Cancer at 15th World Conference on Lung Cancer
Mar 21, 2013: Ohr Pharma Announces Results From OHR/AVR118 Phase II Trial In Cancer Cachexia
Mar 14, 2013: GTx Announces Publication Of Enobosarm Phase II Trial Results In The Lancet Oncology
Mar 04, 2013: PsiOxus Therapeutics Completes Patient Enrollment For Phase II Wasting Disease Therapeutic MT-102
Oct 08, 2012: GTx To Present Scientific Poster Presentations On Enobosarm At International Society Of Geriatric Oncology
Aug 28, 2012: Aeterna Zentaris Recruits First Patient For Phase IIA Trial In Cancer Cachexia With AEZS-130
Jun 25, 2012: GTx Announces Presentation On Enobosarm's Improvement In Physical Function In Cancer Patients With Both Low And Normal Testosterone Levels
Mar 08, 2012: Michael E. DeBakey Veterans Affairs Medical Center Initiates Phase Ila Trial In Cancer Cachexia With Aeterna Zentaris’s Ghrelin Agonist, AEZS-130
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Cancer Cachexia, H1 2015
Number of Products under Development for Cancer Cachexia - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Number of Products under Development by Companies, H1 2015 (Contd..1)
Number of Products under Investigation by Universities/Institutes, H1 2015
Comparative Analysis by Late Stage Development, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Comparative Analysis by Early Stage Development, H1 2015
Products under Development by Companies, H1 2015
Products under Development by Companies, H1 2015 (Contd..1)
Products under Investigation by Universities/Institutes, H1 2015
Cancer Cachexia - Pipeline by Acacia Pharma Ltd., H1 2015
Cancer Cachexia - Pipeline by Aeterna Zentaris Inc., H1 2015
Cancer Cachexia - Pipeline by Amgen Inc., H1 2015
Cancer Cachexia - Pipeline by Aphios Corporation, H1 2015
Cancer Cachexia - Pipeline by Atara Biotherapeutics, Inc., H1 2015
Cancer Cachexia - Pipeline by Eli Lilly and Company, H1 2015
Cancer Cachexia - Pipeline by GTX, Inc., H1 2015
Cancer Cachexia - Pipeline by Helsinn Healthcare S.A., H1 2015
Cancer Cachexia - Pipeline by Incyte Corporation, H1 2015
Cancer Cachexia - Pipeline by Novartis AG, H1 2015
Cancer Cachexia - Pipeline by Ohr Pharmaceutical Inc., H1 2015
Cancer Cachexia - Pipeline by PsiOxus Therapeutics, Ltd., H1 2015
Cancer Cachexia - Pipeline by Radius Health, Inc., H1 2015
Cancer Cachexia - Pipeline by RaQualia Pharma Inc., H1 2015
Cancer Cachexia - Pipeline by Vicus Therapeutics, LLC, H1 2015
Assessment by Monotherapy Products, H1 2015
Assessment by Combination Products, H1 2015
Number of Products by Stage and Target, H1 2015
Number of Products by Stage and Mechanism of Action, H1 2015
Number of Products by Stage and Route of Administration, H1 2015
Number of Products by Stage and Molecule Type, H1 2015
Cancer Cachexia Therapeutics - Recent Pipeline Updates, H1 2015
Cancer Cachexia - Dormant Projects, H1 2015
Cancer Cachexia - Dormant Projects (Contd..1), H1 2015
Cancer Cachexia - Discontinued Products, H1 2015

List of Figures
Number of Products under Development for Cancer Cachexia, H1 2015
Number of Products under Development for Cancer Cachexia - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Comparative Analysis by Early Stage Products, H1 2015
Assessment by Monotherapy Products, H1 2015
Number of Products by Top 10 Targets, H1 2015
Number of Products by Stage and Top 10 Targets, H1 2015
Number of Products by Top 10 Mechanism of Actions, H1 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015
Number of Products by Top 10 Routes of Administration, H1 2015
Number of Products by Stage and Top 10 Routes of Administration, H1 2015
Number of Products by Top 10 Molecule Types, H1 2015
Number of Products by Stage and Top 10 Molecule Types, H1 2015

Ordering:
Order Online - http://www.researchandmarkets.com/reports/3106216/
Order by Fax - using the form below
Order by Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

Product Name: Cancer Cachexia - Pipeline Review, H1 2015
Web Address: http://www.researchandmarkets.com/reports/3106216/
Office Code: SCD2STYH

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Product Format</th>
<th>Quantity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic (PDF) - Single User:</td>
<td>USD 2000</td>
</tr>
<tr>
<td>Electronic (PDF) - Site License:</td>
<td>USD 4000</td>
</tr>
<tr>
<td>Electronic (PDF) - Enterprisewide:</td>
<td>USD 6000</td>
</tr>
</tbody>
</table>

Contact Information
Please enter all the information below in BLOCK CAPITALS

<table>
<thead>
<tr>
<th>Field</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Title:</td>
<td>Mr ☐ Mrs ☐ Dr ☐ Miss ☐ Ms ☐ Prof ☐</td>
</tr>
<tr>
<td>First Name:</td>
<td>________________________</td>
</tr>
<tr>
<td>Last Name:</td>
<td>________________________</td>
</tr>
<tr>
<td>Email Address: *</td>
<td>________________________</td>
</tr>
<tr>
<td>Job Title:</td>
<td>________________________</td>
</tr>
<tr>
<td>Organisation:</td>
<td>________________________</td>
</tr>
<tr>
<td>Address:</td>
<td>________________________</td>
</tr>
<tr>
<td>City:</td>
<td>________________________</td>
</tr>
<tr>
<td>Postal / Zip Code:</td>
<td>________________________</td>
</tr>
<tr>
<td>Country:</td>
<td>________________________</td>
</tr>
<tr>
<td>Phone Number:</td>
<td>________________________</td>
</tr>
<tr>
<td>Fax Number:</td>
<td>________________________</td>
</tr>
</tbody>
</table>

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:

Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer: Please transfer funds to:

<table>
<thead>
<tr>
<th>Account number</th>
<th>833 130 83</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sort code</td>
<td>98-53-30</td>
</tr>
<tr>
<td>Swift code</td>
<td>ULSBIE2D</td>
</tr>
<tr>
<td>IBAN number</td>
<td>IE78ULSB98533083313083</td>
</tr>
<tr>
<td>Bank Address</td>
<td>Ulster Bank, 27-35 Main Street, Blackrock, Co. Dublin, Ireland.</td>
</tr>
</tbody>
</table>

If you have a Marketing Code please enter it below:

Marketing Code: _______________________

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:

(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World